Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Up 50.0% in September

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the recipient of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 2,400 shares, an increase of 50.0% from the August 31st total of 1,600 shares. Based on an average trading volume of 62,800 shares, the short-interest ratio is presently 0.0 days.

Enzon Pharmaceuticals Price Performance

Shares of ENZN stock opened at $0.12 on Friday. The firm has a market capitalization of $8.91 million, a price-to-earnings ratio of 12.00 and a beta of 0.51. The stock has a fifty day moving average of $0.15 and a 200 day moving average of $0.13. Enzon Pharmaceuticals has a 52 week low of $0.06 and a 52 week high of $0.24.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.